EP
NWBO

Eudaimonia Partners’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Eudaimonia Partners’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,700
Closed -$7K – 1562
2021
Q1 		$7K Buy
+4,700
New +$7K ﹤0.01% 1273

Other funds holding NWBO

MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $592M AUM 25.27% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Eudaimonia Partners's NWBO Position: Q2 2021 in Review

Eudaimonia Partners sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2021, closing a stake of 4,700 shares — an estimated $7K sold.

Eudaimonia Partners first reported a position in NWBO in Q1 2021 and held it in 1 quarter. The position peaked at $7K in Q1 2021. 13 funds tracked by Wall St. Rank hold NWBO as of Q2 2021.

  • Eudaimonia Partners reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 4,700 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2021, an estimated $7K.
  • Eudaimonia Partners first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Northwest Biotherapeutics, Inc. Common stock position peaked at $7K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.